The administration of proper medication is essential to the treatment of a health complication. As such, medical practitioners need to enforce proper measures in the issuance of medicine to enhance the betterment of patients (Bojesen et al. 375). The purpose of this study is to evaluate the value of medicines through the utilization of a case study. This study will be in line with the code of conduct for Oncologists since the medical practitioner in this scenario deals with cancer patients. Since the maintenance of confidentiality is essential to the success of the medical practice, the practitioners’ and patient’s name will be changed to uphold the discretion policies in accordance with the Health Support Workers and Adults Social Care Workers (McAlpine et al. 471). Additionally, this presentation will explore the effects, use, and the side effects of a variety of medications while also analyzing compliance issues arising from the utilization of these drugs. Finally, this paper will outline consent issues that arise from the issuance of medication between the patient and the health practitioners.
This case study involves a 40 year old who was admitted in the author’s clinic. Jane was received in the author’s hospital after experiencing challenges in her Stage III ovarian cancer. She had previously undergone surgery and six cycles of chemotherapy with taxol and carboplatin. Previously, she had received a reemission and showed positive performance for nearly three months before of her CA 125 level started rising. Nonetheless, the CT scans did not reveal any signs of diseases in spite of her body anomalies. These changes were mainly a result of the rising amount of emotional and psychological distress. In addition to these medical complications, Jane also experienced asthma attacks throughout her chemotherapy period. The treatment approaches recommended by her initial doctor were affecting her overall recovery since she did not play a role in determining the type of treatment she received (Pharoah et al. 368). When her case was presented to the author, there was a need to engage different treatment approaches to enhance the betterment of her health. This situation was largely accredited to the fact that she had uncontrolled pain, while suffering continuous spells of vomiting and breathlessness due to the removal of the malignant cancer cells in her ovary (Kuchenbaecker et al. 168). However, Jane preferred to stop taking cancer treatment and instead spend more time with her family since she suffers from a terminal disease. Her emotional and psychological pain continually drove her into feeling the need to spend more time at home than in the hospital.
For a fact, almost every living individual in the planet has at one time received some form of medication to aid in the betterment of his or her health. The administration of these medications can be in the form of tropical creams, syrups or pills due to the diversity in the manufacturing and administration process (Andriole et al. 153). For this study, the medicines to be analyzed include carboplatin, taxol and theophylline.
Carboplatin is an anticancer drug used in chemotherapy to enhance the effectiveness the treatment. It is primarily used in the treatment of ovarian cancer although its relevance is extensive among other forms of cancer (Aghajanian et al. 2042). For instance, it can be used to minimize the effects of lung, breast and cervical cancer. It is also influential to the treatment of the central nervous system and germ cell tumors. It can also be used in the preparation of stem cells and bone marrow transplants. In the treatment of ovarian cancer, this drug is administered by infusion into the veins (Aghajanian et al. 2042). As such, it can be described as an intravenous drug. This provision is largely accredited to the fact that it has a high absorption potential making it lesser challenging for the body to incorporate its effectiveness during treatment (Pharoah et al. 367). In some cases, however, this drug should be issued through the intra-peritoneal approach. Specifically, it should be directed into the peritoneal cavity in the abdomen to improve the response of the patient’s body (Rikova et al. 197).
The medical practitioner should do the administration of this drug cautiously as the amount to be issued is dependent on many health factors. For starters, an individual’s height and weight or other general health problems can compromise the effectiveness of the drug. This situation is largely accredited to the fact that one’s body response is largely based on the amount of the drug issued (Pujade-Lauraine et al. 1307). Therefore, doctors should determine the right amount to be administered to the patients to prevent the occurrence of avoidable medical complications. Due to the effects posed by chemotherapy, the utilization of carboplatin can cause the development of vomiting and nausea, blood test abnormalities and general body weakness (Pearce et al. 390). Consequently, accurate identification of these symptoms is essential to the treatment of the complication due to the abnormal rise in the magnesium levels caused by the long-term consumption of this drug.
Taxol is referred to as Paclitaxel and is used in chemotherapy. It is widely classified as a texane, antimicrotubule agent and a plant alkaloid. It is used in the treatment of ovarian, breast, lung, bladder, esophageal and prostrate cancer. According to (Ledermann et al. 1388), this medicine is essential to the neutralization of solid tumor cancers due to its influential chemical properties. It can also be used in the treatment of Kaposi sarcoma. Due to the fact that the chemical properties contained in this form of medication have a large impact on a patient’s health, physicians need to employ proper analysis procedures to minimize the possibilities of erroneously issuing the medication (Ferreira et al. 1567). It is mainly issued as an infusion or injection into the veins of the patient (Bolton et al. 101). As such, it can be described as an intravenous drug. However, it is worth mentioning that this drug is an irritant. According to Permuth-Wey et al. (1627), the chemicals contained in this medicine can cause the inflammation of the veins to which it is administered. Therefore, if the medication makes its way out of the veins, it can cause damage tissue damage.
There are common allergic reactions reported after taking this medication. As a result, patients and nurses administering the drug ought to be careful during the drug administration process to minimize the chances of negatively impacting the health of an individual (Miow et al. 1900). This drug is issued over various schedules depending on the patient’s response to the development of medical complications. Due to the nature of the chemical properties contained in this medication, there is no pill form for paclitaxel. Just like the administration of carboplatin, the amount of taxol issued to a patient is dependent on their height, weight, general health problems and the type of condition being treated (Bowtell et al. 669). Therefore, doctors determine the amount of medication to be issued depending on these factors.
Theophylline is commonly used in the treatment of breathing problems among premature infants. However, it has influential impacts in the prevention of, chest tightness, shortness of breath, and wheezing caused by asthma, emphysema, chronic bronchitis and other chronic lung diseases (Pakhale et al. 153). This provision is largely accredited to the fact that it opens and relaxes air passages in the lungs, therefore, making it easier to breath (Moorman et al. 57). This medication is commonly prescribed to patients experiencing asthmatic conditions and other complex medical complications such as lung cancer (Pavord et al. 653). The effectiveness of its remedy makes it an appropriate alternative in the treatment of complex health complications. It is mainly administered as a tablet, solution, syrup and a capsule through ingestion. In most occasions, the drug is taken after intervals of six, eight or twelve hours depending on the patient’s body requirements and the nature of their medical complication (Wenzel et al. 2459). The drug is best taken few hours before meals to minimize the chances of the patients experiencing breathing difficulties when taking their food.
In spite of the fact that Jane has been admitted to hospital because of her ovarian cancer condition and asthma, it is worth acknowledging the fact that the poor treatment approaches utilized by her doctors initially contributed to her current condition. As such, the primary cause for her being admitted is because of the distress caused by failed medical procedures in the initial stages of her treatment (Sigh et al. 24). As mentioned earlier, she constantly experiences continuous spells of vomiting and breathlessness. In spite of the fact that these are common symptoms for the advancement of asthma, influential treatment approaches should be administered since she also suffers from other medical complications that could cause these symptoms. The medical practitioner should ensure that the administration of other medication is ceased before the commencement of the chemotherapy session aimed at neutralizing the development of her ovarian cancer. According to Hartmann and Noralane (456), the seizure of earlier medical plans before the commencement of chemotherapy is an influential medical approach as it enables the medical practitioner to determine the cause of body reactions and to determine the side effects of the medication used. As such, this approach would be influential to Jane’s health.
The utilization of carboplatin needs to be done with a lot of precaution. Jane constantly complained of severe abdominal pain during her treatment sessions and diarrhea. The fact that she felt nauseous on multiple occasions affected her ability to eat comfortably without body distress. Jayson et al. (1380) argue that these are common side effects of using this drug in chemotherapy and the medical practitioners need to evaluate the patient’s response before implementing a particular medical procedure (Gomez et al. 57). In this case, Jane experiences these episodes because of the treatment measures employed. Owing to the fact that she has a family, her inevitable end of life mounts pressure on the amount of time she has left to live. This situation heightens her stress levels and constantly leads to an increase in her body temperatures (Shen et al. 1628). She also has an infant but is restricted from breast-feeding due to the effects of carboplatin to the production of milk. Since Jane constantly felt that she was not fulfilling her maternal obligations to her child, the heightened level of stress led to her depression and this situation led to the worsening of her medical condition.
Compliance is defined as the degree to which an individual’s conduct corresponds with his health or medical advice (Erickson et al. 145). In spite of the fact that this is an old definition, the rationale beyond this idea is still maintained in the concurrent generation. As such, a patient who does not comply with the provisions speculated by the medical practitioner either directly or indirectly fails to uphold the medical compliance agreement during the issuance of drugs (Harris et al. 37). As a result, the patient can be categorized as a passive recipient of healthcare. However, the law recognizes a patient’s autonomy to the compliance provisions overseeing the betterment of their healthcare. If an individual has an appropriate mental capacity to make rational decisions, enforcing care treatment on them without respecting their choices is not only illegal but also unethical (Oza et al. 934). Consequently, health practitioners should only implement medical practices once the patients agree to the terms. In this case, Jane is allowed to have her decisions respected. If she felt that the continuation of the treatment procedures affected her maternal responsibilities and there was a need to terminate the treatment approaches to spend time with her family, the author should respect her decision since the legal system acknowledges her autonomy over medical compliance.
In conclusion, it is essential to note that the implementation of palliative care in the end of life care treatment is influential to the betterment of a patient’s health. As such, family members, caregivers and other medical practitioners need to embrace proper initiatives when implementing healthcare practices. Judy’s treatment can be made more influential than her initial one if she is involved in the decision making process. She feels that there is a need to spend more time with her family members and minimize the amount of medication she receives during her palliative care. This approach indicates that the emotional pain felt due to the absence from her family is often more severe than the physical pain endured due to the medical complication. As such, this study is influential in outlining that pharmaceutical pain is lesser challenging as opposed to psychological pain.
Works cited
Aghajanian, Carol, et al. "OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer." Journal of Clinical Oncology 30.17 (2012): 2039-2045.
Andriole, Gerald L., et al. "Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up." Journal of the National Cancer Institute (2012).
Bojesen, Stig E., et al. "Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer." Nature genetics 45.4 (2013): 371-384.
Bolton, Kelly L., et al. "Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer." Nature genetics 48.1 (2016): 101-101.
Bowtell, David D., et al. "Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer." Nature Reviews Cancer 15.11 (2015): 668-679.
Crum, Christopher P. "Preventing ovarian cancer." Journal of Clinical Oncology 34.2 (2016): 198-199.
Erickson, Britt K., et al. "Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center." Gynecologic oncology 133.2 (2014): 142-146.
Ferreira, Manuel AR, et al. "Genome-wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype." Journal of Allergy and Clinical Immunology 133.6 (2014): 1564-1571.
Gomez, Jose L., et al. "Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40." Journal of Allergy and Clinical Immunology 136.1 (2015): 51-58.
Harris, Holly R., et al. "Abstract B37: Menstrual cycle characteristics, PCOS, and ovarian cancer risk." Clinical Cancer Research 22.2 Supplement (2016): B37-B37.
Hartmann, Lynn C., and Noralane M. Lindor. "The role of risk-reducing surgery in hereditary breast and ovarian cancer." New England Journal of Medicine 374.5 (2016): 454-468.
Jayson, Gordon C., et al. "Ovarian cancer." The Lancet 384.9951 (2014): 1376-1388.
Kuchenbaecker, Karoline B., et al. "Identification of six new susceptibility loci for invasive epithelial ovarian cancer." Nature genetics 47.2 (2015): 164-171.
Ledermann, Jonathan, et al. "Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer." New England Journal of Medicine 366.15 (2012): 1382-1392.
McAlpine, Jessica N., et al. "Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention." American journal of obstetrics and gynecology 210.5 (2014): 471-e1.
Miow, Q. H., et al. "Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer." Oncogene 34.15 (2015): 1899-1907.
Moorman, Jeanne E., et al. "National surveillance of asthma: United States, 2001-2010." Vital & health statistics. Series 3, Analytical and epidemiological studies/[US Dept. of Health and Human Services, Public Health Service, National Center for Health Statistics] 35 (2012): 1-67.
Oza, Amit M., et al. "Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial." The Lancet Oncology 16.8 (2015): 928-936.
Pakhale, Smita, et al. "Effects of weight loss on airway responsiveness in obese asthmatics: Does weight loss lead to reversibility of asthma?." Chest. doi 10 (2015).
Pavord, Ian D., et al. "Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial." The Lancet 380.9842 (2012): 651-659.
Pearce, Celeste Leigh, et al. "Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies." The lancet oncology 13.4 (2012): 385-394.
Permuth-Wey, Jennifer, et al. "Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21. 31." Nature communications 4 (2013): 1627.
Pharoah, Paul DP, et al. "GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer." Nature genetics 45.4 (2013): 362-370.
Pignata, Sandro, et al. "Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial." The Lancet Oncology 15.4 (2014): 396-405.
Pujade-Lauraine, Eric, et al. "Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial." Journal of Clinical Oncology 32.13 (2014): 1302-1308.
Puvanenthiran, Soozana, Alan Michael Seddon, and Helmout Modjtahedi. "Studies of co-expression of cancer stem cell markers and growth factor receptors in human ovarian cancer cells and their responses to treatment with various tyrosine kinase inhibitors." Cancer Research 75.15 Supplement (2015): 5311-5311.
Rikova, Klarisa, et al. "Abstract B197: Proteomic based analysis of ovarian cancer pathways." Molecular Cancer Therapeutics 12.11 Supplement (2013): B197-B197.
Shen, Hui, et al. "Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer." Nature communications 4 (2013): 1628.
Singh, S., et al. "Hyperthermic Intra-Thoracic Chemotherapy (HITeC) for the management of recurrent ovarian cancer involving the pleural cavity." Gynecologic oncology case reports 9 (2014): 24-25.
Wenzel, Sally, et al. "Dupilumab in persistent asthma with elevated eosinophil levels." New England Journal of Medicine 368.26 (2013): 2455-2466.
